Abstract
Summary This study reviews the cases of three pediatric patients with central nervous system (CNS) tumors found to have CHEK2 mutations. Germline testing, obtained in one case, demonstrates that the CHEK2 mutation is germline in nature. We speculate that CHEK2 may be playing a role in carcinogenesis, and that further reporting of similar cases may help identify a new molecular driver in pediatric CNS tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
